Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Drug Discovery 6, 464–479 (1 June 2007) | doi:10.1038/nrd2111
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
&
Abstract
Aggregation of hyperphosphorylated tau is one of the characteristic neuropathological lesions of Alzheimer's disease and other neurodegenerative disorders. Pharmacological modulation of tau hyperphosphorylation might represent a valid and feasible therapeutic strategy for such disorders. Here, we consider recent evidence supporting the validity of the three most relevant kinases affecting tau hyperphosphorylation — GSK3β, CDK5 and ERK2 — as drug targets and describe progress in the design of inhibitors for these kinases.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
